Inmune Bio, Inc.(INMB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.4M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
INMB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Inmune Bio, Inc. (INMB), a Healthcare sector company. INMB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), Inmune Bio, Inc. reports net income of $-5.4M, free cash flow of $-3.4M. Top institutional holders of INMB by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. INMB trades on the Nasdaq exchange and files with the SEC under CIK 1711754. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inmune Bio, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-5.4M
Free Cash Flow
Q1 2026
$-3.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+257.1% YoYNet Income
-9.3% YoYOperating Income
-11.1% YoYEPS (Diluted)
+11.8% YoYTotal Assets
-18.2% YoYTotal Debt
Op. Cash Flow
+32.3% YoY| Metric | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $50.0K +257.1% | $14.0K | — | $0.00 | $0.00 | — |
| Net Income | $-46.0M -9.3% | $-42.1M -448.1% | $-7.7M +38.3% | $-12.4M -1396.1% | $-831.5K | — |
| Operating Income | $-47.4M -11.1% | $-42.6M -449.7% | $-7.8M +37.7% | $-12.4M -1167.5% | $-981.5K | — |
| EPS (Diluted) | $-1.86 +11.8% | $-2.11 | — | — | — | — |
| Total Assets | $32.4M -18.2% | $39.6M +61.7% | $24.5M +40.9% | $17.4M -5.7% | $18.4M | — |
| Total Debt | — | $15.0M | — | — | — | — |
| Operating Cash Flow | $-22.6M +32.3% | $-33.4M -519.6% | $-5.4M -161.5% | $-2.1M -170.3% | $-761.8K | — |
AI Insight: INMB Ratio Trends
Losses remain deep but ROE and ROA show tentative improvement from their worst levels, while D/E data is too sparse for a firm leverage trend.
• ROE improved from -131.3% in Q1 2025 to -89.5% in Q4 2025, the least negative reading in the observable period.
• ROA recovered from -93.2% in Q4 2024 to -65.1% in Q4 2025, suggesting modestly better asset utilization.
• ROE deteriorated again to -110.2% in Q1 2026, reversing the Q4 2025 improvement and signaling no sustained trend.
• D/E ranged from 0.45 to 0.78 across the period with no clear directional trend; leverage remains moderate for a clinical-stage biotech.
⚠ ROE swung from -89.5% in Q4 2025 back to -110.2% in Q1 2026 — the Q4 improvement has not held.
⚠ OpMargin and NPM are absent throughout; without these, true operating efficiency cannot be assessed.
⚠ ROIC data is missing for Q1 2026 — confirm whether the Q4 2025 reading of -56.8% (best in the series) is sustained.
Get alerted when INMB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Inmune Bio, Inc. including:
Top Institutional Holders of INMB
BlackRock, Inc.
$1.3M1,194,112 shVANGUARD CAPITAL MANAGEMENT LLC
$776.3K687,015 shGEODE CAPITAL MANAGEMENT, LLC
$559.5K494,969 shEverSource Wealth Advisors, LLC
$426.0K3,357 shSTATE STREET CORP
$328.7K290,879 shAQR CAPITAL MANAGEMENT LLC
$305.5K270,317 shUBS Group AG
$286.3K253,340 shGOLDMAN SACHS GROUP INC
$261.7K231,586 shRAYMOND JAMES FINANCIAL INC
$229.7K203,245 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$219.7K194,391 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.3M | 1,194,112 |
| VANGUARD CAPITAL MANAGEMENT LLC | $776.3K | 687,015 |
| GEODE CAPITAL MANAGEMENT, LLC | $559.5K | 494,969 |
| EverSource Wealth Advisors, LLC | $426.0K | 3,357 |
| STATE STREET CORP | $328.7K | 290,879 |
| AQR CAPITAL MANAGEMENT LLC | $305.5K | 270,317 |
| UBS Group AG | $286.3K | 253,340 |
| GOLDMAN SACHS GROUP INC | $261.7K | 231,586 |
| RAYMOND JAMES FINANCIAL INC | $229.7K | 203,245 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $219.7K | 194,391 |
More Healthcare Companies
View all Healthcare →Put INMB on your watchlist
Track score changes the day Inmune Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INMB a good stock to buy?
13F Pro's AI-powered analysis of Inmune Bio, Inc. (INMB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INMB are available on the INMB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INMB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INMB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inmune Bio, Inc.'s investment landscape.